2026-08-24 · ozempic, mounjaro, semaglutide, tirzepatide, glp-1, brand comparison, SURPASS-2, type 2 diabetes

Are Ozempic and Mounjaro the same drug?

No. Both are once-weekly subcutaneous injections FDA-labeled for type 2 diabetes, but they are different molecules from different manufacturers. Ozempic is semaglutide (a GLP-1 receptor agonist) from Novo Nordisk, dosed 0.25 to 2 mg weekly. Mounjaro is tirzepatide (a dual GIP + GLP-1 receptor agonist) from Eli Lilly, dosed 2.5 to 15 mg weekly. Neither is FDA-approved for weight loss — that indication belongs to their sister brands Wegovy and Zepbound.

Which loses more weight, Ozempic or Mounjaro?

In the SURPASS-2 head-to-head trial (Frías 2021, NEJM, n=1,879, 40 weeks), Mounjaro at 15 mg produced −11.2 kg mean weight loss versus −5.7 kg on Ozempic 1 mg — roughly twice as much weight loss on the top Mounjaro dose. HbA1c reduction favored Mounjaro too (−2.30% vs −1.86%). Ozempic's maximum T2D dose was raised to 2 mg after SURPASS-2 was designed, so the trial slightly understates how modern Ozempic 2 mg performs, but Mounjaro still wins the head-to-head at either dose.

Which is cheaper in 2026?

Their US list prices are close — roughly $998/month for Ozempic and $1,079/month for Mounjaro in 2026. Both manufacturers offer commercial-insurance copay cards that can bring out-of-pocket cost to as little as $25/month for eligible patients. Neither has a manufacturer cash-pay vial program at T2D doses in 2026 (Lilly's LillyDirect vial route is Zepbound-only, not Mounjaro). For uninsured patients with T2D, price is roughly a wash.

Does Medicare cover Ozempic or Mounjaro?

Yes — Medicare Part D covers both drugs for their FDA-labeled type 2 diabetes indication. The Part D obesity-drug exclusion does not apply because Ozempic and Mounjaro are labeled for T2D, not weight loss. This is a major reason patients with T2D plus obesity end up on Ozempic or Mounjaro rather than Wegovy or Zepbound, both of which are excluded from Part D for the weight-only indication.

Can I switch from Ozempic to Mounjaro (or the other direction)?

Yes, and it happens often — usually because a formulary changed at January renewal, tolerability stalled, or HbA1c plateaued. A common conversion is Ozempic 1 mg to Mounjaro 5 mg, or Mounjaro 5 mg to Ozempic 1 mg, then continuing titration on the new drug. Expect a few weeks of renewed GI symptoms after each dose step up. Do not self-switch — the molecules are different and the prescriber needs to reissue the prescription and set the starting step.

Do Ozempic and Mounjaro have different side effects?

The side-effect families are the same — the GLP-1 gastrointestinal cluster of nausea, diarrhea, constipation, and vomiting — but incidence differs modestly. At 40 weeks in SURPASS-2, nausea was reported in roughly 22% of Mounjaro 15 mg patients versus 17% on Ozempic 1 mg, and discontinuation-for-adverse-events was 6.4% vs 5.7%. Both carry the same boxed medullary-thyroid-cancer warning and the same class warnings for pancreatitis, gallbladder disease, and acute kidney injury from persistent GI losses.

If I don't have T2D, can my doctor still prescribe Ozempic or Mounjaro for weight loss?

A clinician can legally prescribe either drug off-label for weight loss, but it is usually not the right call in 2026. Insurance rarely covers off-label GLP-1 use, prior-authorization criteria almost always require a diabetes diagnosis, and the on-label weight-loss brands — Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide up to 15 mg) — reach higher doses purpose-built for weight loss. If the goal is weight loss without T2D, Wegovy or Zepbound is the correct starting conversation.

Which should I ask my doctor for?

If you have T2D plus obesity and haven't tried either, most endocrinologists in 2026 lean toward Mounjaro for HbA1c above roughly 8% or when weight loss is a priority — the SURPASS-2 gap is real. Ozempic is the better ask if you already have established cardiovascular disease (Ozempic has a labeled CV-risk-reduction indication from SUSTAIN 6 that Mounjaro does not yet carry), if you are stable on semaglutide with acceptable HbA1c, or if your specific plan formulary covers Ozempic and not Mounjaro.

Ozempic vs Mounjaro

The one-sentence answer

Ozempic (semaglutide) and Mounjaro are both once-weekly injections FDA-approved for type 2 diabetes and used off-label for weight loss; in the SURPASS-2 head-to-head trial, Mounjaro produced roughly twice the weight loss of Ozempic and a slightly larger HbA1c reduction at 40 weeks — but insurance formulary, cash-pay pricing, and titration tolerability decide the answer for most real patients. Neither drug is FDA-approved for weight loss; for the weight-loss-labeled siblings, see Wegovy vs Zepbound.

How Ozempic and Mounjaro differ at a glance

The T2D-labeled siblings of Wegovy and Zepbound share the same molecules — semaglutide and tirzepatide, respectively — but at lower maximum doses and with a different FDA indication. For the molecule-only comparison stripped of brand and dose considerations, see semaglutide vs tirzepatide.

The SURPASS-2 head-to-head result

SURPASS-2 (Frías 2021, NEJM, n=1,879, 40 weeks) is the only large randomized trial that directly compared these two drugs in adults with type 2 diabetes inadequately controlled on metformin. Patients were randomized to tirzepatide 5 mg, 10 mg, or 15 mg weekly, or to semaglutide 1 mg weekly (Ozempic’s maximum labeled T2D dose at the time the trial was designed). All arms continued background metformin.

• HbA1c reduction at 40 weeks: −2.30% at tirzepatide 15 mg vs −1.86% at semaglutide 1 mg.
• Weight loss at 40 weeks: −11.2 kg at tirzepatide 15 mg vs −5.7 kg at semaglutide 1 mg.
• HbA1c under 7.0%: achieved by 86% of tirzepatide 15 mg patients vs 79% on semaglutide 1 mg.
• HbA1c under 5.7% (normoglycemic range): 46% on tirzepatide 15 mg vs 19% on semaglutide 1 mg.

One important caveat about the dose comparison. SURPASS-2 was designed and enrolled before Novo Nordisk raised Ozempic’s labeled maximum T2D dose to 2 mg in Q1 2022, so the trial’s semaglutide arm was capped at 1 mg. Real-world 2026 Ozempic 2 mg outperforms the 1 mg arm reported here — post-hoc modeling and the SUSTAIN FORTE trial (Frías 2021, Lancet, semaglutide 2 mg vs 1 mg) suggest an additional roughly 0.2–0.3% HbA1c and 1–2 kg of weight loss on 2 mg over 1 mg. Even after that adjustment, tirzepatide 15 mg still separates from semaglutide 2 mg on both endpoints — but the gap is closer to 3–4 kg than the raw 5.5 kg the trial as published implies. The Chinese subgroup of SURPASS-2 (Ji 2024, Lancet Diabetes Endocrinol) reproduced the same directional result in a different population.

Weight loss off-label — realistic expectations

Neither Ozempic nor Mounjaro is FDA-approved for weight loss. Weight loss is a real, expected effect of both drugs at their T2D-labeled doses, and clinicians can and do prescribe them off-label for weight loss, but the on-label weight-loss indication belongs to their molecular siblings — Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide up to 15 mg). If you do not have T2D, the on-label pathway is Wegovy or Zepbound; if the choice between those is the actual question, Wegovy vs Zepbound is the head-to-head walkthrough.

What patients actually see on the maximum T2D dose:

• Mounjaro 15 mg: roughly −11 kg (about −11% of body weight) at 40 weeks in SURPASS-2. Longer 72-week data from the same-molecule obesity trial SURMOUNT-1 (Jastreboff 2022, NEJM) landed at −20.9%, but that used the higher Zepbound label and a longer follow-up.
• Ozempic 2 mg: roughly −7 to −9% of body weight at one year in mixed T2D and off-label real-world cohorts. The 2 mg arm of SUSTAIN FORTE landed at approximately −7 kg at 40 weeks in T2D patients; real-world US clinic data on the 2 mg dose has clustered in the same range.

The pattern is consistent: at their T2D-labeled maximum doses, Mounjaro delivers more weight loss than Ozempic on average, but neither reaches the weight loss that Wegovy or Zepbound produce at their higher obesity-labeled doses. See zepbound for weight loss and tirzepatide weight loss for the on-label numbers.

Mechanism differences

Semaglutide activates the GLP-1 receptor alone. GLP-1 slows gastric emptying, quiets appetite through central hypothalamic pathways, and stimulates glucose-dependent insulin release from the pancreatic beta cell. This is the mechanism behind every first-generation weekly incretin, from Ozempic to Wegovy to Rybelsus.

Tirzepatide activates two gut-hormone receptors — GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is the older-known incretin; adding a GIP agonist arm to a GLP-1 backbone produces additive appetite suppression, additive insulin secretion, and (based on preclinical rodent data from Coskun 2018, Molecular Metabolism, and Frías 2018) additive weight loss beyond what GLP-1 alone reaches. The Jastreboff SURMOUNT-1 obesity data at 20.9% mean weight loss is the clearest downstream evidence that the extra receptor matters.

Mechanistically, the extra receptor drives most of the SURPASS-2 delta. The two drugs are not just different doses of the same idea — they belong to different pharmacological classes, and that is why the SURPASS-2 result is real rather than an artefact of dose selection.

Cost and insurance in 2026

Both drugs are expensive at US list price, and both are usually reached through insurance rather than cash-pay. All figures are typical 2026-Q2 US retail; confirm current numbers with your insurer, pharmacy, or manufacturer.

The Medicare Part D coverage picture is the single biggest structural reason patients with T2D plus obesity end up on Ozempic or Mounjaro rather than Wegovy or Zepbound in 2026. The federal Part D obesity-drug exclusion in the Social Security Act still stands and continues to block Wegovy and Zepbound from Part D coverage for a weight-only indication. Ozempic and Mounjaro are labeled for T2D, not weight loss, so the exclusion does not apply and both are routinely covered under Part D when a T2D diagnosis is documented. For patients paying cash at T2D dosing, there is no direct-purchase vial program for either drug — Lilly’s LillyDirect self-pay vial program is Zepbound-only and does not carry Mounjaro SKUs. For a fuller multi-brand cost walkthrough, see GLP-1 cost and insurance coverage.

Side effect profile compared

Both drugs share the class-level GLP-1 gastrointestinal cluster — nausea, diarrhea, constipation, and vomiting — most pronounced during titration and stepping down substantially by month three on a stable maintenance dose. Head-to-head incidence at 40 weeks in SURPASS-2 was close, with a small edge to semaglutide on tolerability:

Both drugs carry the same class-level serious risks: the boxed warning for medullary thyroid C-cell tumors (rodent data; contraindicated with a personal or family history of MTC or MEN2), uncommon acute pancreatitis, gallbladder disease (particularly during rapid weight loss), and dehydration-related acute kidney injury from persistent vomiting or diarrhea. Practical GI-management guidance is identical for both drugs — small protein-forward meals, steady hydration, and holding a titration step an extra four weeks when the current dose is not tolerated. See Ozempic side effects and managing GLP-1 side effects for the full titration playbook that applies to both.

Titration schedules compared

Both drugs are titrated up in fixed monthly steps to control the GI adverse-event burden. Mounjaro has more steps and takes longer to reach maximum, but with a slower onboarding that some patients find easier to tolerate.

• Ozempic: 0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1 mg × 4 weeks → 2 mg maintenance. Approximately 16 weeks to reach the labeled maximum T2D dose. Four total steps.
• Mounjaro: 2.5 mg × 4 weeks → 5 mg × 4 weeks → 7.5 mg × 4 weeks → 10 mg × 4 weeks → 12.5 mg × 4 weeks → 15 mg maintenance. Approximately 24 weeks to reach the labeled maximum. Six total steps.

The practical implication: Mounjaro’s slower titration typically means better GI tolerability step-for-step, but a longer runway before the full HbA1c and weight-loss effect appears. Patients who prioritize a fast HbA1c drop and can tolerate the higher-step doses reach steady state on Ozempic sooner; patients who have been GI-sensitive on prior GLP-1 exposure often prefer Mounjaro’s smaller step increments. Both drugs permit holding a step an extra four weeks if a given level is not tolerated.

Which is easier to switch to if the other fails

Switching between Ozempic and Mounjaro is common in clinical practice — the most frequent triggers are a January formulary change that drops one brand’s coverage, a plateau at the top dose of one drug, or persistent GI intolerance on the current brand.

Because the molecules are different, a switch is not dose-for-dose. A common approximate conversion:

• Ozempic 1 mg → Mounjaro 5 mg as an equivalent starting step, then continue Mounjaro titration monthly toward the target.
• Mounjaro 5 mg → Ozempic 1 mg in the opposite direction, then adjust based on tolerability and glycemic response.
• Ozempic 2 mg → Mounjaro 7.5 or 10 mg for patients who have already reached the top Ozempic dose without adequate response.

Prescribers usually reissue the prescription rather than expect a patient to self-switch, and expect a few weeks of renewed GI adjustment after each new dose step up. Insurance-driven forced switches at January formulary renewal are the single most common trigger — commercial and Medicare Advantage plans routinely move one brand on and the other brand off their preferred tier from year to year, and the switch protocol above is what most clinics use when the letter arrives.

When Ozempic is the better answer

Three concrete cases where Ozempic is usually the right pick even accounting for the SURPASS-2 gap:

1. Established cardiovascular disease. Ozempic carries an FDA-labeled indication for major-adverse-cardiovascular-event (MACE) risk reduction in adults with T2D plus established CVD, based on the SUSTAIN 6 outcomes trial (Marso 2016, NEJM, n=3,297; 26% MACE reduction over roughly 2 years). Mounjaro’s dedicated cardiovascular-outcomes trial, SURPASS-CVOT, is reading out in 2026 but is not yet reflected in the Mounjaro label. If MACE risk reduction is a clinical priority, the labeled indication currently favors Ozempic.
2. Stable on semaglutide, no plateau, acceptable HbA1c. Patients doing well on Ozempic 1 or 2 mg with HbA1c at or under target and no acceleration of weight gain generally have no reason to switch. The switch cost (renewed titration, renewed GI symptoms, and a stretch of prior-authorization paperwork) is real; if the current regimen is working, staying is usually correct.
3. Formulary coverage. Any commercial plan or Medicare Part D plan that covers Ozempic but not Mounjaro on the preferred tier makes Ozempic the practically-cheaper and administratively-easier ask, and step-therapy protocols on many plans require an Ozempic trial before Mounjaro will be authorized.

When Mounjaro is the better answer

Three concrete cases where Mounjaro is usually the better pick:

1. HbA1c above roughly 8% or when weight loss above 10% is a stated goal. The SURPASS-2 gap on both endpoints matters most when the starting HbA1c is high or the weight-loss target is aggressive. If Ozempic 2 mg has already been tried without adequate response, escalating to Mounjaro is the next standard step rather than continuing to plateau.
2. New-diagnosis T2D with T2D remission as the goal. The 46% of Mounjaro 15 mg patients who reached HbA1c under 5.7% in SURPASS-2 — versus 19% on semaglutide 1 mg — is the strongest single number in favor of Mounjaro when the clinical target is not just control but drug-free remission. The Rosenstock 2024 SURPASS follow-up analysis reinforced the same durability signal.
3. Formulary coverage. Any commercial plan or Medicare Part D plan that covers Mounjaro but not Ozempic on the preferred tier makes Mounjaro the practical answer, regardless of the head-to-head data. Coverage moves — routinely, at January renewal — and the correct drug is always the one your plan will pay for after prior authorization clears.

Frequently asked questions

Are Ozempic and Mounjaro the same drug? No. Both are once-weekly subcutaneous injections FDA-labeled for type 2 diabetes, but they are different molecules from different manufacturers. Ozempic is semaglutide (a GLP-1 receptor agonist) from Novo Nordisk, dosed 0.25 to 2 mg weekly. Mounjaro is tirzepatide (a dual GIP + GLP-1 receptor agonist) from Eli Lilly, dosed 2.5 to 15 mg weekly. Neither is FDA-approved for weight loss — that indication belongs to their sister brands Wegovy and Zepbound.

Which loses more weight, Ozempic or Mounjaro? In the SURPASS-2 head-to-head trial (Frías 2021, NEJM, n=1,879, 40 weeks), Mounjaro at 15 mg produced −11.2 kg mean weight loss versus −5.7 kg on Ozempic 1 mg — roughly twice as much weight loss on the top Mounjaro dose. HbA1c reduction favored Mounjaro too (−2.30% vs −1.86%). Ozempic’s maximum T2D dose was raised to 2 mg after SURPASS-2 was designed, so the trial slightly understates how modern Ozempic 2 mg performs, but Mounjaro still wins the head-to-head at either dose.

Which is cheaper in 2026? Their US list prices are close — roughly $998/month for Ozempic and $1,079/month for Mounjaro in 2026. Both manufacturers offer commercial-insurance copay cards that can bring out-of-pocket cost to as little as $25/month for eligible patients. Neither has a manufacturer cash-pay vial program at T2D doses in 2026 (Lilly’s LillyDirect vial route is Zepbound-only, not Mounjaro). For uninsured patients with T2D, price is roughly a wash.

Does Medicare cover Ozempic or Mounjaro? Yes — Medicare Part D covers both drugs for their FDA-labeled type 2 diabetes indication. The Part D obesity-drug exclusion does not apply because Ozempic and Mounjaro are labeled for T2D, not weight loss. This is a major reason patients with T2D plus obesity end up on Ozempic or Mounjaro rather than Wegovy or Zepbound, both of which are excluded from Part D for the weight-only indication.

Can I switch from Ozempic to Mounjaro (or the other direction)? Yes, and it happens often — usually because a formulary changed at January renewal, tolerability stalled, or HbA1c plateaued. A common conversion is Ozempic 1 mg to Mounjaro 5 mg, or Mounjaro 5 mg to Ozempic 1 mg, then continuing titration on the new drug. Expect a few weeks of renewed GI symptoms after each dose step up. Do not self-switch — the molecules are different and the prescriber needs to reissue the prescription and set the starting step.

Do Ozempic and Mounjaro have different side effects? The side-effect families are the same — the GLP-1 gastrointestinal cluster of nausea, diarrhea, constipation, and vomiting — but incidence differs modestly. At 40 weeks in SURPASS-2, nausea was reported in roughly 22% of Mounjaro 15 mg patients versus 17% on Ozempic 1 mg, and discontinuation-for-adverse-events was 6.4% vs 5.7%. Both carry the same boxed medullary-thyroid-cancer warning and the same class warnings for pancreatitis, gallbladder disease, and acute kidney injury from persistent GI losses.

If I don’t have T2D, can my doctor still prescribe Ozempic or Mounjaro for weight loss? A clinician can legally prescribe either drug off-label for weight loss, but it is usually not the right call in 2026. Insurance rarely covers off-label GLP-1 use, prior-authorization criteria almost always require a diabetes diagnosis, and the on-label weight-loss brands — Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide up to 15 mg) — reach higher doses purpose-built for weight loss. If the goal is weight loss without T2D, Wegovy or Zepbound is the correct starting conversation.

Which should I ask my doctor for? If you have T2D plus obesity and haven’t tried either, most endocrinologists in 2026 lean toward Mounjaro for HbA1c above roughly 8% or when weight loss is a priority — the SURPASS-2 gap is real. Ozempic is the better ask if you already have established cardiovascular disease (Ozempic has a labeled CV-risk-reduction indication from SUSTAIN 6 that Mounjaro does not yet carry), if you are stable on semaglutide with acceptable HbA1c, or if your specific plan formulary covers Ozempic and not Mounjaro.

How this article was researched

This article draws on the SURPASS-2 head-to-head trial (Frías 2021, NEJM) for direct efficacy comparison, the Chinese subgroup analysis (Ji 2024, Lancet Diabetes Endocrinol), the Rosenstock 2024 SURPASS follow-up for T2D remission data, the SUSTAIN 6 cardiovascular-outcomes trial (Marso 2016, NEJM) for the Ozempic CV indication, the SUSTAIN FORTE trial (Frías 2021, Lancet) for the semaglutide 1 mg vs 2 mg dose comparison, current FDA prescribing information for Ozempic and Mounjaro, and publicly available Novo Nordisk and Eli Lilly cash-pay pricing. Coverage and pricing details reflect 2026-Q2 US commercial and Medicare Part D norms and will move; confirm specific numbers with your insurer, clinician, or manufacturer before making a decision.